Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Renerve Limited ( (AU:RNV) ) just unveiled an update.
ReNerve Limited has appointed experienced corporate strategist and governance specialist Maja McGuire as Non-Executive Chair of its board, formalising her transition from interim chair as part of the company’s ongoing board renewal process. The move strengthens ReNerve’s leadership and governance framework as it pursues commercial expansion and further development of its peripheral nerve repair technologies, with management highlighting McGuire’s track record in ASX-listed medical device and life sciences companies as a key asset in executing its growth and commercialisation strategy for high-margin products in a fast-expanding global market.
More about Renerve Limited
ReNerve Limited is an Australian biotechnology and medical device company focused on developing innovative solutions for peripheral nerve injury repair. Founded by a neurosurgeon and medtech researchers, the company offers a portfolio of scientifically backed products, including its FDA-cleared NervAlign Nerve Cuff, dermal and amniotic tissue products, and next-generation nerve conduits and guides aimed at improving surgical outcomes and patient quality of life in the rapidly growing global nerve repair market.
Average Trading Volume: 563,831
Technical Sentiment Signal: Strong Sell
Learn more about RNV stock on TipRanks’ Stock Analysis page.